| | | | | | | | | | |
|
Dockets Management
|
| Dockets Entered
On July 25, 2006
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1998P-0151
|
| Introduction Of Downed Cattle Into The Food Supply
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
| 2004E-0393
|
| Patent Extension for Uroxatral (Alfuzosin hydrochloride), U.S. Patent No. 4,661,491
|
|
|
| 2004E-0444
|
| Patent Extension for BONIVA (ibandronate), U.S. Patent No. 4,927,814
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2006P-0071
|
| 513 (e) Reclassification of Tissue Adhesive For Soft Tissue Approximation
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
| 2006P-0205
|
| Require Vitamin D be added to cereal-grain products
|
|
|
| 2006P-0223
|
| Switch Plan B and equivalent EC drugs from prescription-only to OTC status without age restrictions, exempt from prescription -dispensing requirement any new drug eligible for filing an ANDA
|
|
|
| 2006P-0291
|
| Determine whether Eloxatin (Oxaliplatin has been voluntarily withdrawn or withheld from sale for safety or efficacy reasons
|
|
|
| 2006P-0298
|
| To permit an ANDA Suitability for Eloxatin (Oxaliplatin for injection)
|
|
|
| 2006P-0299
|
| Determine whether Eloxatin (Oxaliplatin for Injection) 50 mg and 100 mg sterile lyophilized powder vials (NDA #21-492 has been withdrawn for safety or effectiveness reasons
|
|
|
| 1998P-0151
|
| Introduction Of Downed Cattle Into The Food Supply
|
|
|
| C 7530
|
| M Lukasiewicz
|
| Vol #:
|
| 319
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
| C 761
|
| L Hamilton
|
| Vol #:
|
| 21
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
| C 539
|
| United State Senate
|
| Vol #:
|
| 45
|
|
|
| 2004E-0393
|
| Patent Extension for Uroxatral (Alfuzosin hydrochloride), U.S. Patent No. 4,661,491
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004E-0444
|
| Patent Extension for BONIVA (ibandronate), U.S. Patent No. 4,927,814
|
|
|
| C 1
|
| Hoffmann-La Roche Inc
|
| Vol #:
|
| 1
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| C 17007
|
| M. Reese
|
| Vol #:
|
| 188
|
|
|
| C 17008
|
| T. Snow
|
| Vol #:
|
| 188
|
|
|
| C 17009
|
| K. Sweeney
|
| Vol #:
|
| 188
|
|
|
| C 17010
|
| S. Bass
|
| Vol #:
|
| 188
|
|
|
| C 17011
|
| A. McKane
|
| Vol #:
|
| 188
|
|
|
| C 17012
|
| S. Shrauger
|
| Vol #:
|
| 188
|
|
|
| C 17013
|
| D. Troxell
|
| Vol #:
|
| 188
|
|
|
| C 17014
|
| M. Citrano
|
| Vol #:
|
| 188
|
|
| | | | | | | | |
|
|
| EC 666
|
| Ms. Robin Miller
|
| Vol #:
|
| 3
|
|
|
| EC 667
|
| Ms. Marie Wolfe
|
| Vol #:
|
| 3
|
|
|
| 2006P-0205
|
| Require Vitamin D be added to cereal-grain products
|
|
|
| SUP 1
|
| Rutgers, State University of New Jersey
|
| Vol #:
|
| 2
|
|
|
| 2006P-0223
|
| Switch Plan B and equivalent EC drugs from prescription-only to OTC status without age restrictions, exempt from prescription -dispensing requirement any new drug eligible for filing an ANDA
|
|
|
|
|
|
|
| SUP 1
|
| State of Wisconsin, Department of Justice
|
| Vol #:
|
| 1
|
|
|
| 2006P-0291
|
| Determine whether Eloxatin (Oxaliplatin has been voluntarily withdrawn or withheld from sale for safety or efficacy reasons
|
|
|
| ACK 1
|
| FDA/ DDM to Sicor Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
|
| CP 1
|
| Sicor Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2006P-0298
|
| To permit an ANDA Suitability for Eloxatin (Oxaliplatin for injection)
|
|
|
| ACK 1
|
| FDA/ DDM to AAC Consulting Group
|
| Vol #:
|
| 1
|
|
|
| CP 1
|
| AAC Consulting Group
|
| Vol #:
|
| 1
|
|
|
| 2006P-0299
|
| Determine whether Eloxatin (Oxaliplatin for Injection) 50 mg and 100 mg sterile lyophilized powder vials (NDA #21-492 has been withdrawn for safety or effectiveness reasons
|
|
|
| ACK 1
|
| FDA/DDM to Rothwell, Figg, Ernst & Manbeck, P.C.
|
| Vol #:
|
| 1
|
|
|
| CP 1
|
| Rothwell, Figg, Ernst & Manbeck, P.C.
|
| Vol #:
|
| 1
|
|